Spots Global Cancer Trial Database for mutations
Every month we try and update this database with for mutations cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| The Aim is to Identify Recurrent Genomic Mutations and/or Predisposing Polymorphisms in Patients With Sporadic Cases of Multiple Myeloma | NCT05331313 | Multiple Myelom... | DNA sequencing | 18 Years - | Hospices Civils de Lyon | |
| BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC) | NCT01562028 | Lung Cancer | Erlotinib Bevacizumab | 18 Years - | ETOP IBCSG Partners Foundation | |
| Clinical and Genomic Registry of MDS in Asia | NCT03169296 | Myelodysplastic... | 18 Years - | The University of Hong Kong | ||
| Resistance to Oral Therapy in Lung Cancer | NCT04546282 | Non Small Cell ... | Description of ... | 18 Years - 90 Years | University Hospital, Montpellier | |
| Liquid Biopsy in Mature B-cell Tumors | NCT03280394 | Mature B-Cell N... | Liquid Biopsy | 18 Years - | Oncology Institute of Southern Switzerland | |
| Tumor Molecular Profiling in Patients With Prostate Cancer | NCT05573789 | Prostate Cancer Metastatic Pros... | Tumor molecular... | 18 Years - | Hellenic Cooperative Oncology Group | |
| Germline Mutations in Pancreatic Adenocarcinoma | NCT03982446 | Germline Mutati... Pancreatic Canc... Predisposition,... Hereditary Canc... | Mutations | 18 Years - 90 Years | Hellenic Cooperative Oncology Group | |
| Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes | NCT02619565 | Myelodysplastic... | blood samples | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Tumor Molecular Profiling in Patients With Prostate Cancer | NCT05573789 | Prostate Cancer Metastatic Pros... | Tumor molecular... | 18 Years - | Hellenic Cooperative Oncology Group | |
| Tumor Molecular Profiling in Patients With Prostate Cancer | NCT05573789 | Prostate Cancer Metastatic Pros... | Tumor molecular... | 18 Years - | Hellenic Cooperative Oncology Group | |
| LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations | NCT01726738 | Stage III Melan... Stage IV Melano... Unresectable Me... BRAF Mutant Mel... | BRAF inhibitor ... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Clinical and Genomic Registry of MDS in Asia | NCT03169296 | Myelodysplastic... | 18 Years - | The University of Hong Kong | ||
| Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer | NCT03724994 | Periampullary A... Periampullary C... Pancreatic Canc... | Gemcitabine | 18 Years - | Lund University | |
| LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations | NCT01726738 | Stage III Melan... Stage IV Melano... Unresectable Me... BRAF Mutant Mel... | BRAF inhibitor ... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations | NCT01726738 | Stage III Melan... Stage IV Melano... Unresectable Me... BRAF Mutant Mel... | BRAF inhibitor ... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| NGS in AML Relapse | NCT03582241 | Acute Myeloid L... | 18 Years - | University Hospital, Strasbourg, France | ||
| Study of Blood Components as Probable Prognostic and Predictive Markers of Response to Treatment in Advanced Colon and Rectal Cancers | NCT02979470 | Colon Cancer St... Rectum Cancer, ... Colon Cancer St... Colon Cancer St... Colon Cancer St... | 18 Years - 70 Years | AC Camargo Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
